Skip to main content
Teaser
Kapseln
Teaser
Teaser

GMP Chitosan, medical device chitosan, pure chitin, pharma chitosan, chitosan derivatives, GMP, Quality, producer | Heppe Medical Chitosan

SARS-CoV-2 research with chitosan - publications to date

The corona virus disease COVID-19 has changed the world. To combat the pandemic, researchers and companies around the world are working to develop vaccines and medicines. Chitosan also has potential in the area of vaccine development and functionalization of protective equipment such as respirators. We have prepared summaries of recent publications on chitosan as an aid in the fight against corona.

Viral safety of chitosan

What about the viral safety of chitosan? Here, we would like to present an interesting publication about the viral safety of chitosan. Chitosan can be applied as a virus-free biopolymer for medical products in human, as the deacetylation process of chitin is sufficient for virus inactivation, shown by Park et al (2015). The researchers from Korea used chitin from Heppe Medical Chitosan to show that viruses are efficiently inactivated during the deacetylation process from chitin to chitosan.

Publications in May & June 2016 - Chitosan Oligosaccharides

This time the focus is on the small ones - Production and application of chitosan oligosaccharides:

In May and June 2016, 639 articles about chitosan, regarding mostly the topics nanoparticles, pharmaceutical preparations und evaluation studies, were published. China (128 articles), United States (42) and India (21) were leading countries in chitosan research.

Chitosan and SARS-CoV-2

The corona virus disease COVID-19 has changed the world since early 2020 in many ways. To combat the pandemic, researchers and companies around the world develop vaccines and medicines. Chitosan has potential in the area of vaccine development and functionalization of protective equipment such as respirators. We prepared reviews of recent publications about chitosan in the fight against corona.

Congress and fairs

Meet us in person 2024:

  • 14th PBP World Meeting/ Research Pharm, Vienna, Austria, 18.-21.03.2024
  • EPNOE Workshop on Analytics of Polysaccharides, ETH Zürich, Zürich, Switzerland, 25.-26.06.2024
  • CPHI, Milan, Italy, 08.-10.10.2024
  • MEDICA 2024, Düsseldorf, Germany, 11.-14.11.2024

To arrange an appointment please contact Katja Richter via This email address is being protected from spambots. You need JavaScript enabled to view it.

Contact

  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
    Germany
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.